Cancer vascular, smooth muscle, extracellular matrix(ECM) and its

Cancer has long been regarded as an
independent disease of only neoplastic cells i.e. a disease of single cell
type. Substantial information has been gathered about the genetic changes in
the neoplastic cells that promote tumorigenesis and metastasis. However,
advanced studies have shown that tumours are heterogeneous neoplasms composed
of different types which not only includes cancer cells but also mesenchymal
cells, endothelial cells, immune cells, fibroblasts/myofibroblasts, glial, epithelial
cells, fat, vascular, smooth muscle, extracellular matrix(ECM) and its secreted
extracellular molecules. Cancerous cells modify and recruit non-cancerous cells
from local or distant host tissue to the tumour microenvironment. These
non-neoplastic cells that constitute the tumour microenvironment are the
supporting cells that help the neoplastic cells in tumour development by
providing ECMs, growth factors, cytokines, vascular networks and extracellular
molecules acting in autocrine and/or paracrine manner.  Recent studies have shown that along with the
cancer cells within the tumour, the non-cancerous cells in the tumour
microenvironment are also heterogeneous in their molecular signatures which is
termed as tumour microenvironment heterogeneity. These    result in cell-to-cell variations in genetic
expression, gene signature and post-translational modifications. This poses a
significant challenge in the treatment of cancer because of drug resistance
which occurs extensively in all types of cancer.

The main reason for this is that targeted
drugs have been developed against single or multiple aberrant molecular
signatures based on the diagnosis of a mixed population of cancer cells in most
cases from a single biopsy. Understanding the specific driving forces behind
different sub-types of intra-tumour heterogeneity

We Will Write a Custom Essay Specifically
For You For Only $13.90/page!

order now

there will be greater improvement in cancer
treatment. Here the  extrinsic factors
that include the components of the tumour microenvironent  and that act on the cancer cells to influence
their genotypes and phenotypes .

have been discussed.






Fibroblasts are the primary cell types in the
normal connective tissue stroma and are the primary producers of the
non-cellular scaffold – the extracellular matrix.

Fibroblasts are responsible for  the deposition of fibrillar ECM that includes
type I, type III and type V collagen and fibronectin. They also contribute to
the formation of the basement membrane by secreting type IV collagen and

The connective tissue and the ECM are
continually remodelled through a dynamic process of ECM protein production and
degradation by fibroblast-derived matrix metalloproteinases (MMPs). Fibroblasts
are also responsible for wound repair.

However, the cancer-associated fibroblasts are
functionally and phenotypically distinct from the normal fibroblasts which are
in the same tissue but not in tumour microenvironment.

within the tumour stroma are identical to the activated fibroblasts in
wounds by their spindyloid appearance and the expression of ?-SMA (smooth
muscle actin). They are distinct in the sense that CAFs are perpetually activated
neither reverting to normal phenotype nor undergoing apoptosis and elimination.
There are several theories regarding the origin of CAFs . Firstly, the
activation of the tissue resident fibroblasts and secondly, the local cancer
cells or epithelial cells undergoing epithelial-to-mesenchymal transition (
EMT)  and finally, the migration and
activation of a marrow-derived cell .

    Experimentally,  factors such as TGF-? can induce normal
fibroblasts to express ?-SMA. However, it is not clear that these
experimentally activated cells acquire other characteristics of CAFs and also
if the phenotype will be stable. The second theory is the EMT . EMT is the
biologic process in which epithelial cells lose their cell-to-cell polarity and
cell-cell adhesion and gain migratory and invasive properties to become
mesenchymal stem cells. Apart from EMT of cancer cells to CAFs , EMT of
surrounding normal epithelial cells may also be an additional source of cells
for CAF formation. Recent studies have also shown that bone marrow-derived
precursor cells invade tumours and function as CAFs . It is not clear whether
these cells are activated as a result of influence of the tissue environment or
if they are a subset of cells within the marrow with an already activated
phenotype and are recruited to the site of tumours.

CAFs produce many growth factors like transforming growth factor (TGF-?)
, hepatocyte growth factor , insulin growth factor ½ , which lead to  proliferation and invasion of cancer cells .
They also secrete chemokines such as monocyte chemotactic protein 1,
interleukin 1 to stimulate proliferation of tumour cells.

CAFs also produce MMPs mostly MMP-9, MMP-2 and
other matrix modifying enzymes which include urikinase- type plasmonigen activator(uPA)
that degrade the ECM  and support tumour
invasion and metastasis . CAFs also produce SDF-1 that stimulates tumour growth
directly. SDF-1 signaling can also stimulate angiogenesis by recruiting EPCs
into the tumour stroma.   





Immune cells like monocytes, macrophages,
neutrophils, lymphocytes are recruited by the tumour cells and thereafter, reside
in the tumour stroma. Infact, at the early stage of tumorigenesis the immune
system of the host can eliminate a significant portion of the premalignant
cells even before their initiation. However, sometimes the cancerous cells
evade the immune system and stay at a dormant stage for a long time called the
equilibrium stage. When these cells are mutated they escape the immune defence
system and start to proliferate rapidly to form a tumour. In other words, the
tumour microenvironment is in an immunosuppressive state where the suppressed
immune cells benefit the tumour by promoting angiogenesis, tumour survival and
metastasis.   After the monocytes are actively recruited
into tumours along defined chemotactic gradients which are  chemotactic ligands that create chemical
concentration gradients that organisms move towards or away  , they reside and differentiate into  tumour-associated macrophages ( TAMs) . TAMs
constitute the major portion of the immune cells in the tumour stroma. TAMs
appear to be preferentially attracted to and retained in areas of necrosis (unprogrammed cell death caused due to external factors such
as infection,trauma and unregulated digestion of cellular components),  and hypoxia ( deficiency of oxygen reaching
the tissues) where they become phenotypically altered and upregulate
hypoxia-induced transcription factors. TAMs rather than being tumoricidal also
adopt a protumoral phenotype at both primary and metastatic sites.

Macrophages also release VEGF, HGF, MMP2 and
IL-8 that influence endothelial cell behaviour and ultimately stimulate the formation
of blood vessels. Neutrophils are also stimulators of angiogenesis. Additional immune
cells do not play much important role in carcinogenesis . They are not
consistent residents of the stroma  and
they are restricted to only specific types of cancer.










is the physiological process through which new blood vessels form from
pre-existing vessels. For cancer cell growth angiogenesis is important because
it supplies nutrients and oxygen which is needed for tumour growth. Many
components of stroma are responsible for initiation of angiogenesis out of which
CAFs play an important role in synchronizing events of angiogenesis by
secretion of many ECM molecules and growth factors such as TGF-?, VEGF,
fibroblast growth factor. It also secretes SDF-1 where SDF-1 signalling is
responsible for recruiting endothelial progenitor cells (EPCs) into the tumour
stroma to form new blood vessels known as vascular mimicry. CAFs also produce a
significant amount of SPARC ( secreted protein acidic and rich in cysteine)
responsible for the regulation of angiogenesis. CAFs also secrete many MMPs
which  causes the  initiation of angiogenesis by the degradation
of the basement membrane,  sprouting of
endothelial cells, regulation of pericyte attachment. As the tumour grows
rapidly there are increased chances of intratumoral hypoxia which promotes
angiogenesis by the production of many secreted factors such as
hypoxia-inducible factors , angiopoietin 1, angiopoietin 4, placental growth
factor, platelet-derived growth factor B. However, these neoangiogenic vessels
are non-uniformly distributed, irregularly shaped, inappropriately branched, tortuous
often ending blindly. These do not have the classical hierarchy of arterioles,
capillaries, venules and oten have arteriovenous shunts. These vessels are
varioubly fenestrated and leaky which are pathways for cancer cells to enter
circulation to initiate metastasis.


recent years medical oncology has focused largely on specific therapeutic
approaches with the aim of identifying patient subpopulations that would
benefit from these therapeutic strategies. The exploration of therapeutic
resistance has largely focused on tumour cells . However, recent studies have
suggested that the mechanisms of therapeutic resistance not only depend on
alterations in the tumour cells but also in the tumour stroma


co-culture experiments showed that within a solid tumour fibroblasts are not
passive elements and could potentially respond and affect therapy. It has been
seen that irradiated or damaged fibroblasts could better support tumour cell
growth than non-irradiated fibroblasts. Stromal derived hepatocyte growth
factor ( HGF) is responsible for rendering tumour cells resistant to BRAF
inhibition in cell lines  that harbour
the BRAF mutation. Moreover, abundance of HGF expression in patients correlated
with reduced responsiveness to drug treatment. These examples show the
importance of assessing potential stromal mediators of inherent resistance and
highlight the challenge of elucidating how therapeutic treatment could elicit
resistance through unforeseen stromal changes. The response of the supporting
stroma to treatment may show a more complicated picture in which
stress-response programs  in these cells
may be limiting treatment efficacy by providing an effective  protective environment for tumour cells.


is speculated that tumour vasculature serves as a barrier to optimal drug
delivery. The blood vessels in the tumour are compressed as the dense nature of
tumour  restrains the tumour vasculature
and disrupts the efficient blood flow, thus elevating the interstitial pressure
. This may obstruct movement within and across tumour vessels . Recent studies
have shown that in order to reduce the interstitial pressure and improve vessel
 flow, cytoreduction of stroma  through the enzymatic destruction of
hyaluronan is a possible option. Cytoreduction is literally the reduction in
the number of cells. Moreover, normalization of leaky vascular beds through
VEGFA pathway inhibition has also been suggested to transiently increase drug
delivery in solid tumours.  Paracrine signalling from endothelial cells within
this niche has been shown to increase chemoresistance by inducing a
stem-cell-like phenotype in a subset of colorectal tumour cells62. Similarly, hypoxic regions of tumours can harbour and support the
survival of colon cancer stem cells during chemotherapy63.  These studies suggest that
distinct niches within a tumour could support and instruct tumour regrowth
following treatment and highlight the unanticipated effects that therapeutic
interventions can have on non-tumour cell components, which can then limit
treatment efficacy.


immune system is an active component of the disease as it recognizes cancer
cells. However, tumour cells evade the immune system due to defects in antigen
presentation and loss in antigenicity. This leads to malignancies and is one of
the major reasons for patient to become refractory to treatment. Tumour cells
also escape from the immune system by modifying tumour microenvironment in an
immune-suppressive state. Infact, immunotherapy refers to the harnessing of the
patient’s immune surveillance to cure the cancer. Several of them have shown
promising results.However, there are some reports of resistance to
immunotherapy. Intrinsic resistance
is shown in patients who fail to evoke T cell responses and antitumor activity.
Generally,patients with immunodeficient virus infection, who have received
transplants, or  elderly people may not
have a strong systemic immune response because of a decrease in their total
T-cell pool 64, 65. Moreover, many
tumor antigens are also expressed in healthy cells, which would lower the
response of T cells to these antigens 66. In the tumor
microenvironment, secretion of TGF-? and IL-10 could inhibit the function of T
cells 67, 68.  microenvironment
In the
context of anti-angiogenic therapy, tumours may be rendered refractory to
anti-VEGF therapy by a pro-inflammatory micro-environment that includes
multiple cell types such as myeloid cells and TAMs that secrete factors
compensating for VEGF loss to support angiogenesis64. Depletion of MDSC expansion and recruitment that is mediated
predominantly by secretion of G-CSF in anti-VEGF insensitive experimental
models could rescue responsiveness to VEGF depletion, leading to decreased
vessel density and tumour growth. Expression of checkpoint molecules including
lymphocyte activation gene 3, T cell membrane protein 3, and B and T lymphocyte
attenuator is able to inhibit the activity of T cells in the tumor immature

 The adoptive
cell transfer (ACT) as the name suggests is the transfer of cells into
patients. The cells may originate from the patient or a different individual.
This is a way to therapeutically harness the anti-tumour effects of adaptive
immunity in patients. The aim of ACT is to boost a patient’s anticancer
immunity by transplanting T cells that recognize tumour-specific antigens,
leading to elimination of cancer cells.68.  It is a very effective method but responses
are not always sustained. Recent work  suggests that inflammation, especially the
presence of TNF (tumour necrosis factor-?) secreted by infiltrating macrophages
resulting from the initial tumour response leads to environmental changes that
induce loss of the targeted tumour antigens. In summary, the immune system can
be implicated in both inherent, as well as acquired resistance to targeted





The contribution of TME in the cancer therapeutic
resistance has been discussed above . This discussion elaborates  on the different types of cells that  contribute to the induction of therapeutic
resistance through their independent mechanisms .  Intercellular communication within the tumour
and its heterogeneity both result in increased resistance to various
therapeutic options . Moreover, tumour cells often utilize secreted molecules
such as exosomes to communicate. Thus, it would be promising to target
intratumoral interactions in anticancer therapies because they are largely
responsible for the therapeutic resistance of tumor cells. It was seen that
?-elemene treatment  inhibits transfer of
multidrug resistance-associated miRNAs and thus blocks intercellular
communication in the tumor 115. Myeloid cells develop tumor therapeutic resistance
through alteration of the characteristics of tumor cells, ECM remodelling and
angiogenesis . Co-culture of MTLn3 cancer cells derived from primary bone
marrow-derived macrophages and isolated from cathepsin B- or S-deficient mice
gave results of  impaired cancer cell
invasion than co-culture with macrophages from wild-type mice 14. When combined with sorafenib (an inhibitor of
tyrosine protein kinases) treatment, TANs depletion suppressed cancer growth
and angiogenesis 28. However, this 
is not all as other pathways of myeloid cells-induced therapeutic
resistance should be investigated.  Tumor microenvironment has been
considered to be of great importance in various therapeutic attempts including